CRELUX has announced that it has been selected by Bayer Schering Pharma AG as a provider for structural biology services.
Under the agreement CRELUX will provide structural biology services on three undisclosed target proteins. The work will include all steps from construct design up to a number of complex structures with small molecule inhibitors provided by Bayer Schering Pharma AG.
Under the agreement CRELUX receives fixed and success based payments on a fee-forservice basis.
CRELUX has used its structural biology platform to solve more than 200 crystal and co-crystal structures in contract research agreements for pharma and biotech companies.
The company’s structural biology platform encompasses all steps from target cloning and expression up to high throughput protein crystallization and in-house x-ray crystallography.
“We are especially delighted that the just recently established German big pharma company Bayer Schering Pharma has picked CRELUX for this high value service project. Being so far mainly active for US-based Pharma companies this further validates our business model and helps us tremendously to strengthen our position in Europe” said Dr. Michael Schäffer, CEO of CRELUX.